Global registries for measuring pharmacoeconomic and quality-of-life outcomes: focus on design and data collection, analysis and interpretation.

摘要: Disease registries have traditionally been vehicles for the collection of clinical data, in most instances following a large number patients long time period an observational manner, and enhancing our understanding disease aetiology epidemiology. However, over recent decades, potential additional data analyses to be conducted within framework registry has recognised utilised. This is evident by sheer that are now referenced medical literature, covering vast array therapeutic areas topics much more varied than incidence, prevalence survival. The opportunity collect QOL pharmacoeconomic utilised as countries increased their demands such information regulatory procedures, including pricing reimbursement decisions. need led marked increase undertaken primarily sponsored pharmaceutical industry. offer tremendous opportunities realise improvements care. length involved some unusual advantages health economic analyses; however, these not yet fully exploited.